Mariner
ATOS icon

Mariner’s Atossa Therapeutics ATOS Stock Holding History

Mariner’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-674
Closed -$6.8K – 3486
2025
Q1 		$6.8K Buy
+674
New +$8.18K ﹤0.01% 3420
2024
Q3 		– Sell
-7,061
Closed -$126K – 3291
2024
Q2 		$126K Hold
7,061
– – ﹤0.01% 2907
2024
Q1 		$191K Hold
7,061
– – ﹤0.01% 2789
2023
Q4 		$93.2K Hold
7,061
– – ﹤0.01% 2863
2023
Q3 		$78K Buy
7,061
+67
+1% +$972 ﹤0.01% 2715
2023
Q2 		$132K Hold
6,994
– – ﹤0.01% 2577
2023
Q1 		$76K Buy
6,994
+3
+0% +$33 ﹤0.01% 2617
2022
Q4 		$55K Hold
6,991
– – ﹤0.01% 2602
2022
Q3 		$87K Buy
+6,991
New +$102K ﹤0.01% 2230
2021
Q4 		– Sell
-7,724
Closed -$378K – 1154
2021
Q3 		$378K Buy
7,724
+67
+0.9% +$3.9K ﹤0.01% 898
2021
Q2 		$726K Buy
+7,657
New +$405K ﹤0.01% 732

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mariner's ATOS Position: Q2 2025 in Review

Mariner sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 674 shares — an estimated $6.8K sold.

Mariner first reported a position in ATOS in Q2 2021 and held it in 11 quarters. The position peaked at $726K in Q2 2021. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • Mariner reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mariner sold 674 Atossa Therapeutics shares in Q2 2025, an estimated $6.8K.
  • Mariner first reported a position in Atossa Therapeutics in Q2 2021 and held it in 11 quarters.
  • Mariner's Atossa Therapeutics position peaked at $726K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.